Abstract Search

ea0063p734 | Pituitary and Neuroendocrinology 2 | ECE2019

A phase 2 study assessing osilodrostat in children and adolescent patients with Cushing’s disease – Rationale and methods

Storr Helen L , Shah Nalini , Wojna Judi , Han Kevin , Roughton Michael , Pierre Combes Francois , Pultar Philippe , Savage Martin O

Background: In children, Cushings disease (CD) presents with a combination of weight gain and slowed linear growth. First-line pituitary surgery is the treatment of choice for most patients. In paediatric patients, the transsphenoidal surgical success rate is 60%98% when performed by an expert pituitary surgeon. There is a need for additional pharmacological interventions to control hypercortisolaemia, which are currently limited, in children and adolescents. In ph...

1 shares

ea0073oc3.1 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat is an effective and well-tolerated treatment for Cushing’s Disease (CD): Results from a Phase III, multicentre, randomized, double-blind study with an initial placebo-controlled phase (LINC 4)

Gadelha Monica , MarieBex , Feelders Richard , Heaney Anthony , Auchus Laviola , Gilis-Januszewska Laviola , Witek Przemyslaw , Zhanna Belaya , Zhihong Liao , Chen Ku Witek , Carvalho Davide , Roughton Michael , Wojna Judi , Hofstetter Georg , Pedroncelli Alberto , Snyder Peter

IntroductionOsilodrostat, a potent, oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during a Phase III, randomized-withdrawal study. We now report findings from a Phase III study of osilodrostat in patients with CD that featured an initial double-blind, randomized, placebo-controlled period (LINC 4; NCT02697734).MethodsAdults with CD (mUFC > 1.3 &...

0 shares

Endocrine Abstracts

A phase 2 study assessing osilodrostat in children and adolescent patients with Cushing’s disease – Rationale and methods

Osilodrostat is an effective and well-tolerated treatment for Cushing’s Disease (CD): Results from a Phase III, multicentre, randomized, double-blind study with an initial placebo-controlled phase (LINC 4)

BiosciAbstracts